All-oral CELMoD-based triplet demonstrates clinical activity in relapsed myeloma
The combination of iberdomide, an oral cereblon E3 ligase modulator, with cyclophosphamide and dexamethasone demonstrated efficacy in patients with relapsed/refractory multiple myeloma (MM) who had received two to four previous lines of therapy. These findings, from the phase 2 ICON trial, were reported in The Lancet Haematology. Notably, a majority (85%) of patients in the study were triple drug class-exposed, and a substantial proportion (44%) had triple drug class-refractory disease.

Bispecific antibody therapies demonstrate efficacy in early relapsed myeloma
Bispecific antibody therapies are currently approved for treating patients with multiple relapsed/refractory MM. Topline data from the phase 3 MajesTEC-9 trial reported in a press release show significantly improved progression-free and overall survival with teclistamab monotherapy compared to standard-of-care treatments. These findings, along with the “remarkable” efficacy of teclistamab-daratumumab in the phase 3 MajesTEC-3 trial, demonstrate the promise of bispecifics in the early relapse setting, as early as second-line therapy.

CD4+ T cells mediate CAR-T therapy-related immune toxicities
CAR-T therapy, a transformative treatment for patients with relapsed myeloma is associated with substantial toxicities, including immune-related adverse effects (irAEs). A deeper understanding of the mechanisms and factors that mediate CAR-T therapy-associated irAEs can help predict the risk of toxicities and devise mitigation strategies. A study published in Nature Medicine pinpointed CD4+ CAR-T cells as key mediators of CAR-T therapy-related immune toxicities. The report expands upon results presented at the 2025 IMS Annual Meeting.

Experimental models to investigate myeloma bone disease
Myeloma bone disease, which impacts a majority (70%–80%) of patients with MM, can cause bone pain, thinning/weakness of bones, and increased fracture risk. Experimental preclinical MM-specific testing platforms, such as mouse models and bone marrow organoids, can help uncover mechanisms underlying bone disease pathogenesis and identify therapeutic vulnerabilities. Available and emerging experimental systems in this space were discussed in a recent review, published in Bone.

Multi-omics analysis uncovers antigen escape-driven resistance mechanisms
In a report published in Nature Medicine, researchers used genomic, transcriptomic, and epigenomic profiling to characterize changes to the GPRC5D locus in clonal plasma cells from patients who relapsed after treatment with GPRC5D-targeted T-cell redirecting therapies. Antigen escape, which contributes to development of resistance to targeted therapies, was mediated by three distinct classes of alterations to the GPRC5D locus.

Report outlines practical steps to help address MM healthcare disparities
Sociodemographic factors contribute to healthcare disparities among patients with MM. A report published in Journal of Cancer Education, developed based on multistakeholder discussions at two MM Health Equity Summits, summarizes recommendations for actions that healthcare providers, the broader MM community, policymakers, and patients can take to tackle care disparities.

Delivering high-value MM care in a low- and middle-income country
Global disparities in MM care exist, with optimal care delivery in low- and middle-income countries (LMICs) constrained by many factors, including high cost of/limited access to advanced diagnostic modalities, healthcare infrastructure, and newer therapies. A review published in Journal of Clinical Oncology Practice outlines the framework for delivering high-value MM care in an LMIC, based on clinical evidence as well as region-specific economic and healthcare system-related considerations.